A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis (NCT01317797), a randomized phase 1 study. The primary outcome is Number of Participants With Clinically Significant Clinical Laboratory Results.

2. Clinical Question

3. Trial Design

This is a Phase Ib trial with randomized allocation and quadruple masking recorded in the registry. The registry labels the model as single group, while also listing two namilumab dose groups and a placebo group. These design descriptors are not reconciled in the record, so the precise intended structure should not be inferred from the model label alone. The recorded enrollment is 24.

The active regimens were namilumab 150 mg and namilumab 300 mg, each administered by subcutaneous injection on Days 1, 15 and 29. The placebo was described as matching namilumab and was scheduled on the same days. Patients had mild to moderate rheumatoid arthritis and were on methotrexate treatment. The sponsor was Takeda. The study started in 2011-03, had primary completion in 2013-08, and is recorded as completed.

The stated purpose was primarily to investigate safety and tolerability after repeated injections. The study also planned to measure MT203 in blood, examine the body’s response, and investigate efficacy. Listed secondary outcomes include pharmacokinetic measures such as maximum plasma concentration, time to maximum concentration, exposure over specified intervals, terminal elimination half-life, and pre-dose concentration. A change from baseline in plasma GM-CSF was also listed. Results for these secondary outcomes are not reported in the registry record. The registry record does not report enough detail to clarify randomization procedures, concealment, dose-escalation rules, or the analysis strategy.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: Participants with a diagnosis of mild or moderate rheumatoid arthritis were enrolled into 1 of 3 treatment groups namilumab (MT203) 150mg, namilumab 300 mg or placebo.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety population included all randomized participants who received study drug.

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Clinically Significant Clinical Laboratory Results, measured over From Day 1 Up to Day 118.

The primary endpoint is the number of participants with clinically significant clinical laboratory results, assessed from Day 1 up to Day 118. It is a safety-monitoring outcome, not a direct measure of rheumatoid arthritis symptoms or disease control. Blood was collected for haematology, chemistry and coagulation, while urine was collected for urinalysis. The registry identifies alert values for specified blood tests, but says no alert values were identified for coagulation or urinalysis.

The alert criteria cover liver-related tests, creatinine, glucose, potassium, haemoglobin, erythrocytes, white blood cells, eosinophils and platelet count. They use thresholds defined in relation to laboratory reference limits or specified concentrations and cell counts. These criteria describe when a result would meet the registry’s definition of clinically significant; they do not themselves show that any participant crossed a threshold.

Counting participants who meet an alert criterion can provide a compact way to describe laboratory safety findings across treatment groups. It treats each person as having or not having at least one qualifying result for the endpoint, rather than conveying the magnitude, duration or clinical context of each laboratory change. The registry record does not report the primary endpoint counts, the number of qualifying results by test, or a comparison between groups. Consequently, the endpoint definition is available, but the observed primary outcome is not reported in the registry record.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry identifies the primary outcome as a count of participants with clinically significant laboratory results. At the participant level, this kind of outcome can be understood as whether a person had at least one result meeting an alert criterion during the stated follow-up. A count then records how many participants in a group met that definition. This is distinct from counting every abnormal test result, since one participant may have more than one flagged test. The registry does not report test-level counts or explain how repeated qualifying findings were handled.

What does a participant count capture?

A participant count is easy to interpret as a description of how many people met an outcome definition. It does not show the number of tests performed, the degree by which a result crossed a threshold, or whether an abnormality was temporary or persistent. Nor does a count alone adjust for differences in follow-up or baseline characteristics. The safety population is defined as randomized participants who received study drug. The registry does not report how many participants in each group contributed laboratory data at each assessment or how incomplete measurements were treated.

How should the alert thresholds be read?

The thresholds define the endpoint rather than reporting an effect. The record lists criteria for several chemistry and blood-count measures, including values relative to the upper limit of normal for some tests and explicit limits for others. These rules determine which findings can qualify as clinically significant in the registry outcome. They do not establish how often a threshold was met, whether a finding was judged related to treatment, or whether a clinician considered it consequential. The record says no alert values were identified for coagulation or urinalysis, but those measurements were still listed as collected.

What does randomization contribute?

In general, random allocation is intended to make treatment groups comparable on average with respect to measured and unmeasured characteristics. Masking is intended to reduce the influence of knowledge about assignment on care, assessment or reporting. These are general purposes, not confirmation that allocation was implemented successfully in this trial. The registry records randomized allocation and quadruple masking, but does not report the sequence-generation method, allocation concealment, or which roles were masked. It also labels the model as single group while listing three treatment groups. The record does not explain that discrepancy, so the analysis should not impose a design interpretation beyond the recorded information.

What can be concluded from the adverse-event counts?

Counts are descriptive summaries. A count without a formal comparison or interval estimate does not quantify the precision of a difference between groups. General statistical inference would account for how much information the observations contain and would express uncertainty around an estimated effect. Such an estimate and its uncertainty are not reported for these adverse-event figures. With limited numbers of participants in each group, individual events can have a substantial influence on the observed counts. That is a general reason for caution, not a recalculation of risk or evidence of a particular direction of effect.

The record lists the number at risk and the number affected for serious and other adverse events. These denominators describe the groups used for those summaries; they should not be confused with the enrollment figure or assumed to represent every randomized participant. The record defines the safety population as participants who were both randomized and received study drug. It does not explain any difference between the enrolled population and the participants represented in each event summary.

Are the results adjusted or tested?

No outcome analysis entries are listed in the registry record summarized for this analysis. It does not report a model, a hypothesis test, a confidence interval, or an adjustment for baseline variables for the primary endpoint or the adverse-event counts. A confidence interval, in general, communicates the uncertainty around an estimate under a specified statistical procedure; it is not a guarantee about the range of possible effects. Because no interval is reported, the precision of a comparative effect cannot be assessed from this record. No unadjusted recalculation is presented, and there is no basis to substitute a newly calculated result for a sponsor analysis.

The sample-size assumptions recorded for planning illustrations describe an approach based on an observed effect, equal allocation, a two-sided significance level of 0.05 and a normal approximation. Those statements do not establish the trial’s original design rationale, and no specific planning result is reported in the registry record for this analysis. A planning illustration is not observed power and does not recover the study’s original sample-size justification. The registry record does not report that justification.

Why can count-based data need careful modeling?

In general, count outcomes may be analyzed with methods suited to their distribution and the way observations arise. Over-dispersion occurs when counts vary more than a chosen model expects; ignoring it can make uncertainty estimates misleading. For this endpoint, however, the registry describes a number of participants with an event, rather than a total number of laboratory findings. It does not specify a count model or report data that would support evaluating over-dispersion. Selecting or asserting a model would therefore go beyond the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The trial listed a primary laboratory-safety outcome and multiple secondary outcomes, including several pharmacokinetic measures and change from baseline in plasma GM-CSF. When a study assesses several outcomes or time points, the chance of obtaining at least one apparently notable finding can increase if many comparisons are made. Statistical approaches can address this multiplicity, but the registry record does not report whether any adjustment or prespecified hierarchy was used. The record also does not report interim analyses or a detailed statistical analysis plan.

The primary endpoint covers a period from Day 1 up to Day 118 and involves multiple laboratory domains. The registry describes alert thresholds but does not report how missing tests, partial assessments, or repeated qualifying findings were handled. It does not state whether participants with no available laboratory result were excluded, counted as having no event, or addressed by another method. Those missing-data procedures are not reported in the registry record.

The safety population includes randomized participants who received study drug. The record does not provide corresponding definitions for an intention-to-treat population, a per-protocol population, or populations used for pharmacokinetic and efficacy analyses. It also does not report group-specific laboratory denominators or analysis-set flow. These omissions limit assessment of whether the posted safety counts and the intended primary endpoint use precisely the same participants.

Without a stated multiplicity strategy, missing-data rule and analysis population for each outcome, the registry’s endpoint definitions cannot be translated into a complete account of how the study analyzed its results. The primary outcome counts and associated analyses are not reported in the registry record.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 5% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: non-small cell lung cancer stage iiia (12.5%), coronary artery stenosis (12.5%).

The serious adverse-event figures are counts of participants: 2 of 8 in the namilumab 150 mg group, 0 of 7 in the namilumab 300 mg group, and 0 of 9 in the placebo group. The corresponding counts for other adverse events are 5 of 8, 4 of 7 and 5 of 9. These summaries should be read as observed group descriptions, not as estimates with established precision or as proof of a causal difference.

The registry lists non-small cell lung cancer stage IIIa and coronary artery stenosis as serious-event terms, each at 12.5%. It does not specify in the record which group each term belongs to or provide further context for those events. The adverse-event summary also has a death entry that is not reported in the registry record. That absence of a reported value is not the same as a reported count of zero.

General statistical interpretation of safety counts requires attention to the small group sizes and to how events were defined, collected and attributed. The registry does not report uncertainty intervals, formal comparisons, or event-level details sufficient to assess those points. The figures therefore describe what was posted, without establishing that treatment caused or prevented an event.

12. What the Result Does, and Does Not, Mean

The registry record describes a randomized, quadruple-masked Phase Ib study of namilumab and matching placebo in patients with mild to moderate rheumatoid arthritis on methotrexate. It defines a primary laboratory-safety outcome and records adverse-event counts for the three listed groups. These details help readers understand what the study set out to assess and what safety summaries were posted.

The primary endpoint results are not reported in the registry record. In particular, the number of participants with clinically significant laboratory results in each group and any comparative estimate are absent. As a result, the endpoint definition cannot be treated as a finding. The listed secondary pharmacokinetic and pharmacodynamic outcomes also lack reported results in the information summarized for this analysis, and the trial’s stated interest in efficacy is not an efficacy result.

The serious and other adverse-event counts are descriptive. They do not, on their own, establish that namilumab increased or decreased the chance of an event compared with placebo. No inferential comparison or measure of uncertainty is reported for these counts. The listed serious-event terms are not assigned to a treatment group in the registry record. The death value is not reported in the registry record, so it cannot be interpreted as evidence of no deaths.

More broadly, a completed study record does not by itself provide all the information needed to judge an effect. Interpretation would depend on outcome results, analysis methods, missing-data handling, and the participants included in each analysis. Those details are not reported in the registry record for the primary outcome. The available information supports a careful account of trial design and posted safety summaries, but not a definitive conclusion about treatment benefit, harm, or comparative effectiveness.

13. Why This Trial Matters Statistically

This trial is statistically notable because its primary endpoint is defined as a participant count based on laboratory alert criteria, while the registry does not report the corresponding outcome values or analysis. That distinction matters: a precise endpoint definition is useful for understanding what would be counted, but it is not a substitute for the observed data. Readers can know the intended safety question without knowing its result.

The record also presents a design-description tension. It identifies randomization and quadruple masking, labels the model as single group, and lists two active doses alongside placebo. The registry does not explain how those labels fit together. Statistical interpretation depends on understanding the comparisons a study was designed to make, so uncertainty in the recorded structure should be acknowledged rather than resolved by assumption.

The posted adverse-event summaries illustrate why counts need context. They offer a direct description of participants affected in each group, but provide no formal comparison or uncertainty interval. In a small Phase Ib study, a count can be informative as a safety observation while remaining too imprecise to establish a reliable difference. The listed serious-event terms and unreported death value further show why event-level context and transparent reporting matter.

Finally, the study included several pharmacokinetic and pharmacodynamic outcomes, but those results are not reported in the registry record. This makes clear that a registry’s outcome list and its outcome results are different kinds of information. For clinical researchers, the key statistical lesson is to separate design intent, endpoint definition, descriptive safety data and inferential evidence. Each supports a different level of interpretation.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation is that the registry record does not report results for the primary laboratory-safety endpoint. It provides alert criteria and a follow-up timeframe, but no group counts, effect estimate or uncertainty measure. The primary outcome therefore cannot be quantitatively interpreted from this record.

The adverse-event summaries are limited to group counts, without reported confidence intervals, formal comparisons, or event-level context. The listed serious-event terms are not linked to specific groups in the information. The death value is not reported in the registry record, which prevents a conclusion about the observed death count.

The registry describes randomization and quadruple masking, but does not report implementation details. Its single-group model label sits alongside three listed groups, without explanation. This leaves uncertainty about how the registry’s design classifications correspond to the intended comparisons. Further limitations include the absence of a reported statistical analysis plan, multiplicity procedures, missing-data rules, and outcome-specific analysis populations.

The record lists secondary pharmacokinetic and pharmacodynamic outcomes but does not report results for them in the information summarized for this analysis. It likewise does not provide an efficacy result. The stated enrollment and the numbers represented in adverse-event summaries are not accompanied by a participant-flow account or group-specific laboratory denominators. These gaps constrain assessment of completeness and precision. No sample-size justification is reported in the registry record.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Trial to Evaluate the Safety and Tolerability of Namilumab (MT203) in Patients With Mild to Moderate Rheumatoid Arthritis — NCT01317797.
• Registry record last updated 2015-08-20; status last verified 2015-07.
• Results first posted 2015-08-20.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01317797 is recorded as a completed Phase Ib randomized, quadruple-masked trial sponsored by Takeda. It enrolled patients with mild to moderate rheumatoid arthritis receiving methotrexate and compared listed namilumab dose groups with matching placebo. The primary outcome was the number of participants with clinically significant clinical laboratory results from Day 1 up to Day 118.

The registry defines laboratory alert criteria and posts serious and other adverse-event counts. It does not report primary endpoint results, statistical comparisons, or uncertainty estimates in the record summarized for this analysis. Secondary outcomes include pharmacokinetic measures and change from baseline in plasma GM-CSF, but their results are not reported. The available information supports descriptive interpretation of the design and safety counts, not a definitive comparative conclusion.